CCFM1359 alleviates intestinal motility disorders through the BDNF-TrkB pathway.

Abstract

Intestinal motility disorder is characterised by abnormal intestinal motility function, often resulting in symptoms such as diarrhoea and constipation. Probiotics are increasingly recognised as an effective treatment for gastrointestinal disorders, including intestinal motility disorders. In this study, we used senna extract to induce an animal model of intestinal dysfunction characterised by BDNF downregulation. By assessing relevant indicators of intestinal dyskinesia, we found thatCCFM1359 effectively alleviated the dyskinesia. However, this alleviating effect was nullified when a TrkB receptor inhibitor was introduced, suggesting thatCCFM1359 operates through the BDNF-TrkB pathway. Further analysis revealed thatCCFM1359 likely exerts its beneficial effects by regulating intestinal microecology (increasing the relative abundance ofand valeric acid content while decreasingand butyric acid content), reducing intestinal inflammation (upregulating the anti-inflammatory factorand downregulating pro-inflammatory factorsand), and remodelling intestinal nerves (upregulatingand the excitatory neurotransmitter ACh, while downregulating the inhibitory neurotransmitter nNOS). This study provides a theoretical basis for using probiotics to alleviate intestinal motility disorders.